Alnylam Pharmaceuticals reported a significant increase in total revenues for the fourth quarter of 2025, reaching $1.097 billion, an 85% increase from the previous year. The company achieved GAAP net income of $111.5 million and non-GAAP net income of $169.8 million, marking a shift to profitability. This growth was primarily fueled by strong performance in AMVUTTRA sales and overall TTR net product revenues.

Alnylam Pharmaceuticals reported record-breaking Q3 2025 results with total net product revenue of $851.1 million, led by a significant 165% growth in AMVUTTRA. Net income turned positive at $251.1 million GAAP and $396.2 million non-GAAP. The company raised its full-year guidance for product revenues, reflecting strong commercial execution.

Alnylam posted $594M in total revenue in Q1 2025, supported by robust growth in AMVUTTRA and new regulatory approvals. The company reported a narrower net loss and strong commercial momentum for its ATTR-CM therapy.

Alnylam Pharmaceuticals reported strong revenue growth in Q4 2024, driven by the continued success of AMVUTTRA. The company significantly reduced its net loss YoY while maintaining strong product revenue momentum.

Alnylam Pharmaceuticals reported a 32% increase in net product revenues for the fourth quarter of 2023, reaching $346 million. The company's GAAP net loss was $(137.87) million, or $(1.10) per share. They also provided financial guidance for 2024, projecting combined net product revenues between $1.4 billion and $1.5 billion.

Alnylam Pharmaceuticals reported a 35% year-over-year increase in net product revenues, driven by the successful launch of AMVUTTRA. The company is on track to report topline results from the HELIOS-B Phase 3 study in early 2024 and reported positive topline results from the KARDIA-1 Phase 2 study of Zilebesiran.

Alnylam Pharmaceuticals reported a strong second quarter in 2023, with a 43% year-over-year increase in global net product revenues, reaching $306 million. This growth was primarily driven by the successful launch of AMVUTTRA and increased patient uptake of GIVLAARI and OXLUMO. The company also achieved significant R&D milestones, including submitting APOLLO-B data to the FDA and entering a global strategic collaboration with Roche for zilebesiran.

Alnylam Pharmaceuticals reported a 48% year-over-year increase in global net product revenues, reaching $276 million in Q1 2023, driven by the launch of AMVUTTRA and growth in GIVLAARI and OXLUMO therapies. The company also reported positive first-in-human results for an RNAi therapeutic in the CNS.

Alnylam Pharmaceuticals reported Q4 2022 financial results, with global net product revenues reaching $262 million, contributing to a full-year revenue of $894 million, a 35% increase compared to 2021. The company highlighted the acceptance of its sNDA for ONPATTRO and provided 2023 combined net product revenue guidance of $1,200 million to $1,285 million.

Alnylam Pharmaceuticals reported strong third-quarter results, highlighted by $232 million in global net product revenues, driven by ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. AMVUTTRA's U.S. launch contributed significantly to growth. The company is on track to submit an sNDA for ONPATTRO and anticipates several pipeline milestones.

Alnylam Pharmaceuticals reported second quarter 2022 financial results, achieving global net product revenues of $214 million, a 33% increase compared to the same period last year. The company also received FDA approval of AMVUTTRA for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and reiterated its 2022 financial guidance.

Alnylam Pharmaceuticals reported its Q1 2022 financial results, with global net product revenues of $186.872 million. The company experienced a GAAP net loss of $240.341 million, or $2.00 per share.

Alnylam Pharmaceuticals reported a strong fourth quarter and full-year 2021, achieving global net product revenues of $199 million for the quarter and $662 million for the year, representing an 83% annual growth. The company is guiding for $900 million to $1 billion in combined net product revenues for 2022. Key milestones include the expected launch of vutrisiran and multiple clinical data readouts.

Alnylam Pharmaceuticals reported a combined net product revenue of $167 million for ONPATTRO, GIVLAARI, and OXLUMO in Q3 2021. The company reiterated its 2021 financial guidance, expecting combined net product revenues of $640-$665 million.

Alnylam Pharmaceuticals reported a strong second quarter in 2021, achieving combined net product revenues of $161 million for ONPATTRO, GIVLAARI, and OXLUMO. The company also increased its 2021 revenue guidance range to $640-$665 million.

Alnylam Pharmaceuticals reported first quarter 2021 financial results, achieving combined net product revenues of $136 million for ONPATTRO, GIVLAARI, and OXLUMO. The company also advanced Vutrisiran towards the market with positive results from the HELIOS-A Phase 3 study and submission of a New Drug Application with the U.S. Food and Drug Administration.

Alnylam Pharmaceuticals reported a strong fourth quarter and full year 2020, with global net product revenues reaching $113 million for the quarter and $362 million for the year. The company achieved regulatory approvals for OXLUMO in the EU and U.S., and Leqvio in the EU. Alnylam launched its 'P5x25' strategy and reported positive results from the HELIOS-A Phase 3 study of Vutrisiran.

Alnylam Pharmaceuticals reported a strong third quarter in 2020, with significant growth in ONPATTRO and GIVLAARI sales. The company is also expecting potential approval for OXLUMO and LEQVIO, which could further bolster growth. Alnylam is increasing its full-year revenue guidance for ONPATTRO.

Alnylam Pharmaceuticals reported strong Q2 2020 financial results, driven by the commercial performance of ONPATTRO and GIVLAARI. The company is increasing the midpoint of its full-year revenue guidance for ONPATTRO and achieved year-over-year improvement in its non-GAAP operating loss.

Alnylam Pharmaceuticals reported its Q1 2020 financial results, demonstrating growth in net product revenues driven by ONPATTRO and GIVLAARI. The company is lowering its 2020 revenue guidance for ONPATTRO by 5 percent due to the COVID-19 pandemic and is taking steps to reduce its expense profile. They also completed a $2 billion strategic financing collaboration with Blackstone.

Alnylam Pharmaceuticals reported strong ONPATTRO patient demand and excellent execution by commercial teams in Q4 2019. The company saw significant ONPATTRO new patient growth in the U.S. and EU, and strong initial demand in Japan. Alnylam also became a multi-product commercial company with the early U.S. approval of GIVLAARI in the fourth quarter.